Journal of Cataract & Refractive Surgery
Volume 34, Issue 10 , Pages 1617-1618 , October 2008

Laboratory data and statistical evidence in fluoroquinolone study

References 

  1. Haugen B, Werner L, Romaniv N, Haymore J, Kleinmann G, Mamalis N, et al. Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis. J Cataract Refract Surg. 2008;34:853–858
  2. Levine JM, Noecker RJ, Lane LC, Herrygers L, Nix D, Snyder RW. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J Cataract Refract Surg. 2004;30:2177–2182
  3. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112:1992–1996
  4. Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 2005;112:466–469
  5. McCulley JP, Caudle D, Aronowicz JD, Shine WE. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006;113:955–959
  6. Ong-Tone L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. J Cataract Refract Surg. 2007;33:59–62
  7. Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol. 2005;123:39–44
  8. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3:359–371

PII: S0886-3350(08)00683-4

doi: 10.1016/j.jcrs.2008.06.017

Journal of Cataract & Refractive Surgery
Volume 34, Issue 10 , Pages 1617-1618 , October 2008

Article Tools